Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Lunac Therapeutics led project wins U.K. innovation grant worth $4m

By Chris Newmarker | December 3, 2019

Lunac TherapeuticsLunac Therapeutics (Leeds, U.K.) this week announced that it has won a U.K. innovation grant equivalent to more than $4 million to develop what it describes as an innovative anticoagulant treatment with minimal bleeding risk.

The £3.14 million grant from Innovate U.K.’s Biomedical Catalyst program also went to the Medicines Discovery Catapult and the University of Leeds, which are collaborating with Lunac on the project.

The 18-month preclinical drug discovery project seeks to develop a first-in-class drug to prevent thrombosis, the formation of a blood clot inside a blood vessel. The organizations will work together to optimize and advance the discovery of a new class of highly specific anticoagulant compounds that block an activated clotting enzyme, Factor XII (FXIIa). The researchers say there is strong evidence that inhibition will not increase the risk of bleeding.

“New anticoagulant treatments are desperately needed. Lunac’s research has shown that targeting activated Factor XII has the potential to offer a new treatment option for patients, and we are therefore delighted to have secured Biomedical Catalyst funding to help drive this exciting project forward,” Helen Philippou, scientific founder of LunacTherapeutics, said in a news release. 

News of the U.K. innovation grant comes weeks after Lunac announced it had spun out of the University of Leeds, with £2.65 million ($3.54 million) in funding from a Series A round led by Epidarex Capital and the university.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Johnson & Johnson Merck COVID-19 vaccine
Report: Biden to announce partnership for Merck to make J&J’s COVID-19 vaccine
Johnson & Johnson
8 things to keep in mind related to the FDA advisory meeting on J&J vaccine
master mixes
Air-dryable master mixes replace lyophilization in the manufacturing of molecular assays
COVID-19 therapies vaccines coronavirus
Could a third vaccine shot better protect against COVID-19 variants?

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards